Company: HROW
Filing Date: 2025-08-11
Form Type: 10-Q
Source: 0001641172-25-022980
Chunk: 55

Company: HARROW, INC.
Filing Date: 2025-08-11
Form: 10-Q
Item: Item 1
Chunk 55
---
. back to Samsung, Samsung will develop, manufacture, and supply BYOOVIZ (ranibizumab-nuna) and OPUVIZ (aflibercept-yszy)
(individually, a “Product” and together, the “Products”) for Harrow to commercialize in the U.S. market (the
“Rights”).. In consideration of such Rights, we will make a one-time upfront payment to Samsung, and Samsung will be eligible
to receive additional one-time payments based on the achievement of net sales-based milestones of the Products. In addition to other
mutually agreed terms, we shall pay to Samsung a share of net sales from the Products generated in the U.S. market.

Acquisition
of Commercial Rights to BYQLOVITM

In
June 2025, we announced a licensing agreement whereby we acquired the exclusive U.S. commercial rights to BYQLOVI (clobetasol propionate
ophthalmic suspension) 0.05% from Taiwan-based Formosa Pharmaceuticals. BYQLOVI was recently approved by the FDA for the treatment of
post-operative inflammation and pain following ocular surgery and is the first new ophthalmic steroid in its class in over 15 years.
Harrow expects BYQLOVI to be available in the fourth quarter of 2025.

VEVYE® Access for All

In
March 2025, we announced a patient access program called VEVYE Access for All. The program is designed to increase patient access to
VEVYE at an out-of-pocket cost of $59 or below and, in many cases, reduce the need for prior authorizations, step edits, and other treatment
obstacles facing dry eye patients and their prescribers.

Project
Beagle

During
the first quarter of 2025 we initiated a 360-degree review of opportunities to offer ImprimisRx customers a Harrow-owned FDA-approved
product alternative to a compounded formulation. We call this initiative Project Beagle. In that vein, we began implementing a continuity
of care program to transition approximately 25,000 ImprimisRx patients from our Klarity-C (0.1% cyclosporine) compounded formulation
to VEVYE (0.1% cyclosporine), and we discontinued compounding Klarity-C on June 30, 2025. We also discontinued another related compounded
formulation called Klarity PF. Klarity PF was primarily purchased by a concentrated group